医药生物行业双周报2024年第6期总第104期：创新药首进政府工作报告，关注相关板块投资机会

Investment Rating - The report maintains the investment rating for the pharmaceutical and biotechnology industry [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 2.25%, outperforming the CSI 300 index which rose by 0.91% [2][10] - The report highlights the first mention of "innovative drugs" in the government work report, indicating a positive policy signal for the sector [5][20] - The average PE ratio for the industry is 25.98x, showing an increase from the previous period's 25.47x, and remains below the negative one standard deviation [14] Industry Review - The chemical preparations and other biological products sub-sectors saw the highest gains, with increases of 5.69% and 3.68% respectively, while vaccines and hospitals experienced declines of 2.40% and 1.90% [10] - As of March 15, 2024, 22 listed companies in the industry saw a net increase in shareholder holdings amounting to 658 million yuan, with 15 companies increasing their holdings by 1.302 billion yuan [2] Important Industry News - The State Council released the 2024 version of the "Guidance Catalog for Industrial Structure Adjustment," encouraging the development of five types of pharmaceutical enterprises [17] - The 2024 government work report emphasizes the development of innovative drugs, rare diseases, and child health, marking a significant policy direction [20] Company Dynamics - BeiGene's "Zebutinib" received FDA approval for a new indication in follicular lymphoma, becoming the first of its kind globally [23] - Madrigal Pharmaceuticals' "Resmetirom" received accelerated FDA approval for treating NASH, marking a significant advancement in the treatment of this condition [27] - Bristol-Myers Squibb's "Breyanzi" became the first CAR-T cell therapy approved for treating CLL/SLL, showcasing innovation in cancer treatment [29]